TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26294693

Group type: EXPERIMENTAL
Intervention: Self-sampling kit (n=1000)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Self-sampling kit and £5 voucher on return of sample (n=500)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Self-sampling kit on request (n=500)
Number of subjects: 2000
Study: 24086352

Group type: EXPERIMENTAL
Intervention: Homeopathic Q‐potencies (case history I)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Homeopathic Q‐potencies (case history II)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Case history I (homeopathic Q‐potencies)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (case history I)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (case history II)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Case history II (homeopathic Q‐potencies)
Number of subjects: 44
Study: 21377075

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (IV PCA with fentanyl)
Number of subjects: 64
Study: 21330795

Group type: EXPERIMENTAL
Intervention: Face-to-face collaborative learning in triads (N = 12)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Individual learning (N = 11)
Number of subjects: 47
Study: 17353040

Group type: EXPERIMENTAL
Intervention: C-ACT (Childhood Asthma Control Test)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: C-ACT
Number of subjects: 343
Study: 15072210

Group type: EXPERIMENTAL
Intervention: Analysis of R-R time series including criteria for PAC, atrial bigeminy, trigeminy, and short runs of paroxysmal atrial tachycardia
Number of subjects: 0
Study: 12186498

Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SM-a), including octreotide (OCT) and lanreotide (LRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Somatostatin analogues (SM-a)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 30
Study: 9118661

Group type: EXPERIMENTAL
Intervention: Cisapride (60 mg initially followed by two doses of 30 mg at 8-hr intervals)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7680457

Group type: EXPERIMENTAL
Intervention: Apex electrode positive
Number of subjects: 289

Group type: COMPARATOR
Intervention: Apex electrode negative
Number of subjects: 289
Study: 2949285

Group type: EXPERIMENTAL
Intervention: Cefoxitin 2 g administered once
Number of subjects: 60

Group type: COMPARATOR
Intervention: Piperacillin 4 g administered once
Number of subjects: 60
Study: 30935865

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 97
Study: 29406486

Group type: EXPERIMENTAL
Intervention: Videos with text messages
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Videos-only
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Text messages-only
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 26349552

Group type: EXPERIMENTAL
Intervention: Vancomycin plus flucloxacillin (combination group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vancomycin (standard therapy group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy (vancomycin)
Number of subjects: 60
Study: 23808787

Group type: EXPERIMENTAL
Intervention: Healthy Foods North (HFN) intervention for 12 months
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Healthy Foods North (HFN) intervention
Number of subjects: 136
Study: 22441222

Group type: EXPERIMENTAL
Intervention: Cathodal high-voltage electrical stimulation (HVES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo group (sham treatment with disconnected HVES equipment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between groups after treatment
Number of subjects: 20
Study: 18420939

Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily in addition to disease-modifying anti-rheumatic drugs
Number of subjects: 150

Group type: COMPARATOR
Intervention: No prednisolone (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patients in remission at 2 years
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patients with active disease
Number of subjects: 150
Study: 17585662

Group type: EXPERIMENTAL
Intervention: Sequential acupuncture method
Number of subjects: 144

Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 144
Study: 16304265

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS) and optimal medical therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Optimal medical therapy only
Number of subjects: 16
Study: 12795180

Group type: EXPERIMENTAL
Intervention: Switch therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clinical pathway
Number of subjects: 32
Study: 10643168

Group type: EXPERIMENTAL
Intervention: Immunization activities in WIC including screening for vaccination status, referral to on-site WIC nurse, on-site clinic, or off-site community provider, and issuing food vouchers (3-month supply for up-to-date children, 1-month supply for not up-to-date children).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunization activities in WIC.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral interventions (off-site and on-site).
Number of subjects: 0
Study: 9031992

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg daily for 27 nights (preceded by 2 nights of placebo and followed by 3 nights of placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (2 nights before and 3 nights after zolpidem administration)
Number of subjects: 0
Study: 1523530

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (lyophilized, producing H2O2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lactobacillus suppository
Number of subjects: 60
Study: 6340415

Group type: EXPERIMENTAL
Intervention: Becotide (beclomethasone diproprionate) inhalations
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All patients (Becotide and placebo)
Number of subjects: 26
Study: 3782678

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 gm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31645180

Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy (two 30- to 45-minute sessions weekly for 12 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional drug treatments and routine daily care (Control)
Number of subjects: 90
Study: 30012547

Group type: EXPERIMENTAL
Intervention: eMotion intervention (Web-based program combining behavioral activation and physical activity promotion)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: eMotion intervention
Number of subjects: 62
Study: 26678518

Group type: EXPERIMENTAL
Intervention: Higher-dose media buy (3 times standard dose)
Number of subjects: 8576

Group type: COMPARATOR
Intervention: Standard-dose media buy
Number of subjects: 8576
Study: 26171398

Group type: EXPERIMENTAL
Intervention: Antioxidant diet 10.000 ORAC + alpha‐lipoic acid
Number of subjects: 71

Group type: COMPARATOR
Intervention: Antioxidant diet 10.000 ORAC + placebo
Number of subjects: 71

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 71
Study: 23920107

Group type: EXPERIMENTAL
Intervention: Specific education program on appropriate indications of intravenous lines
Number of subjects: 1910

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 1910
Study: 21914406

Group type: EXPERIMENTAL
Intervention: Modified two layer closure (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: One layer closure (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Two layer closure (Group B)
Number of subjects: 90
Study: 18693456

Group type: EXPERIMENTAL
Intervention: Insulin plus rosiglitazone (4 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Insulin plus metformin
Number of subjects: 60
Study: 16380197

Group type: EXPERIMENTAL
Intervention: Experimental protocol of verbal‐only advice on positioning and attachment, delivered at the first postnatal ward feed
Number of subjects: 370

Group type: COMPARATOR
Intervention: Routine care by a qualified midwife
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 370
Study: 14617267

Group type: EXPERIMENTAL
Intervention: Direct heel loading
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ankle-cuff compression
Number of subjects: 27
Study: 10911006

Group type: EXPERIMENTAL
Intervention: Nesiritide (infused at a rate of 0.015 microg/kg/min)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Nesiritide (infused at a rate of 0.030 microg/kg/min)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Nesiritide (up to 7 days)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard intravenous therapy
Number of subjects: 432
Study: 8769617

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg daily)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Nystatin (4 X 10(6) U)
Number of subjects: 143
Study: 1330127

Group type: EXPERIMENTAL
Intervention: Short-term group therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Brief counselling
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 135
Study: 4073101

Group type: EXPERIMENTAL
Intervention: Ticarcillin (3 g) plus clavulanate potassium (200 mg) administered intravenously
Number of subjects: 78

Group type: COMPARATOR
Intervention: Piperacillin (125 to 200 mg/kg per day) administered intravenously
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanate potassium
Number of subjects: 78

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 78
Study: 31024557

Group type: EXPERIMENTAL
Intervention: Poly-ICLC (1.4 mg subcutaneously, two consecutive daily doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27681227

Group type: EXPERIMENTAL
Intervention: Telecare intervention (SCOPE)
Number of subjects: 124
Study: 26870827

Group type: EXPERIMENTAL
Intervention: Adherence priming (compensation model)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Resource priming (capitalization model)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Supportive resource priming (capitalization model)
Number of subjects: 57
Study: 24933728

Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength training (EMST)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-EMST (after 3 months of detraining)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Post-EMST to post-detraining period
Number of subjects: 10
Study: 22260209

Group type: EXPERIMENTAL
Intervention: Mouthrinse 1
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mouthrinse 2
Number of subjects: 67
Study: 19963228

Group type: EXPERIMENTAL
Intervention: Cognitively enhanced program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional home visitation program
Number of subjects: 0
Study: 18197495

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human growth hormone (rhGH) 0.15 IU/kg daily for 7 days postoperatively
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (menstruum) injection daily for 7 days postoperatively
Number of subjects: 48
Study: 15990570

Group type: EXPERIMENTAL
Intervention: 600 mg daily dose of hydroxyurea
Number of subjects: 115

Group type: COMPARATOR
Intervention: Higher doses of hydroxyurea (900 mg and 1200 mg)
Number of subjects: 115
Study: 12187500

Group type: EXPERIMENTAL
Intervention: Product R
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 10541778

Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Warfarin (10 mg on day 1 and 2.5‐10 mg on days 2‐21)
Number of subjects: 16
Study: 7529484

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 12283629

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dipropyline
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 343489

Group type: EXPERIMENTAL
Intervention: Papaverine (5‐‐10 mg per kg body weight)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30782183

Group type: EXPERIMENTAL
Intervention: Single-dose antimicrobial prophylaxis (AP) with cotrimoxazole
Number of subjects: 1574

Group type: COMPARATOR
Intervention: 3-day antimicrobial prophylaxis (AP) with cotrimoxazole
Number of subjects: 1574
Study: 30067429

Group type: EXPERIMENTAL
Intervention: Posterior composite restorations with glass ionomer cement providing pulp protection
Number of subjects: 194
Study: 26995364

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon counterpulsation (IABC)
Number of subjects: 176

Group type: COMPARATOR
Intervention: pPCI alone
Number of subjects: 176
Study: 24257591

Group type: EXPERIMENTAL
Intervention: Daily monitoring of traumatic symptoms and substance use behaviors using PDAs
Number of subjects: 202

Group type: COMPARATOR
Intervention: No daily monitoring assessments (only pre- and post-monitoring online assessments)
Number of subjects: 202
Study: 22088145

Group type: EXPERIMENTAL
Intervention: Microbicide clinical trial participation (women)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Microbicide clinical trial participation (men)
Number of subjects: 157
Study: 19041143

Group type: EXPERIMENTAL
Intervention: Bipolar diathermy tonsillectomy (BDT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy (CDT)
Number of subjects: 150
Study: 17572380

Group type: EXPERIMENTAL
Intervention: Cognitive load condition
Number of subjects: 3

Group type: COMPARATOR
Intervention: No cognitive load condition
Number of subjects: 3
Study: 15451221

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (n=857)
Number of subjects: 1702

Group type: COMPARATOR
Intervention: Parenteral penicillin (n=845)
Number of subjects: 1702
Study: 11394606

Group type: EXPERIMENTAL
Intervention: Tibial eminence fracture treatment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Anterior cruciate ligament deficiency
Number of subjects: 3

Group type: COMPARATOR
Intervention: Anterior cruciate ligament reconstruction using bone‐patellar tendon‐bone autografts
Number of subjects: 3
Study: 9596326

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional diathermic device
Number of subjects: 45
Study: 8092118

Group type: EXPERIMENTAL
Intervention: Group I: surgery if possible, otherwise biopsy followed by whole-brain irradiation to a total dose of 34 Gy in 4 fractions, VCR (2 mg i.v.), and BCNU (80 mg/m2 i.v.) every 6 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group II: irradiation as Group I plus VP16 (75 mg/m2) every 3 weeks and BCNU (50 mg/m2 i.v.) every 6 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group III: 60 Gy in 30 fractions to the tumor bed plus VCR (2 mg i.v.), BCNU (50 mg/m2 i.v.), and CDDP (15 mg/m2 i.v.) every 6 weeks
Number of subjects: 108
Study: 2979243

Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes (1.91 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low nicotine cigarettes (0.17 mg)
Number of subjects: 10
Study: 28681570

Group type: EXPERIMENTAL
Intervention: Bimatoprost (Lumigan 0.01%), applied bid to the proximal nail fold
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vehicle drops (control group)
Number of subjects: 45
Study: 27006512

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 8494

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 8494
Study: 25073015

Group type: EXPERIMENTAL
Intervention: Caffeine only
Number of subjects: 0

Group type: COMPARATOR
Intervention: UMTS MP only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine and MP
Number of subjects: 0

Group type: COMPARATOR
Intervention: No caffeine and no MP
Number of subjects: 0
Study: 22545738

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Combination of CBASP and nefazodone
Number of subjects: 259

Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 259
Study: 19447020

Group type: EXPERIMENTAL
Intervention: Lutein (12 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lutein (12 mg/day) plus green tea extract (200 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 40
Study: 17218777

Group type: EXPERIMENTAL
Intervention: 1E10 anti-idiotype vaccine (2 mg of aluminum hydroxide-precipitated 1E10 MAb, four biweekly injections followed by six doses at 28-day intervals)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1E10 anti-idiotype vaccine
Number of subjects: 9
Study: 16086128

Group type: EXPERIMENTAL
Intervention: Sniffin' Sticks Screening Test (SSST)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (homogeneous subjects)
Number of subjects: 29
Study: 12196750

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel (EE/LNG)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 8722664

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appropriate medical and surgical therapy
Number of subjects: 0
Study: 2158759

Group type: EXPERIMENTAL
Intervention: Alkalized bupivacaine (0.25% with 8.4% sodium bicarbonate)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unaltered bupivacaine (0.25% with normal saline)
Number of subjects: 120
Study: 448786

Group type: EXPERIMENTAL
Intervention: Oxamniquine (15 mg/kg single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxamniquine (15 mg b.d. for a single day)
Number of subjects: 0
Study: 31176255

Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Static stretching (SS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Without stretching (WS)
Number of subjects: 15
Study: 28219295

Group type: EXPERIMENTAL
Intervention: Pharmaceutical schemas (beliefs about medicines)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correct recall of side effects
Number of subjects: 0
Study: 26936842

Group type: EXPERIMENTAL
Intervention: Red wine (Cabernet Sauvignon variety)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ethanol solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: White wine (Robola variety)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 22954403

Group type: EXPERIMENTAL
Intervention: Colistin and rifampicin combination
Number of subjects: 43

Group type: COMPARATOR
Intervention: Colistin alone
Number of subjects: 43
Study: 21360202

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (water with carbohydrates)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 14
Study: 19944006

Group type: EXPERIMENTAL
Intervention: Sublingual specific immunotherapy (SLIT) for children with allergic rhino-conjunctivitis and seasonal asthma for a duration of no less than three years.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) for pediatric allergic rhinitis and asthma.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study: 17762711

Group type: EXPERIMENTAL
Intervention: Citalopram (7.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14752635

Group type: EXPERIMENTAL
Intervention: 30 mg/kg oral ALA (low-dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 60 mg/kg oral ALA (high-dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 30 mg/kg in two fractions 4 and 6 h before PDT
Number of subjects: 25
Study: 11162974

Group type: EXPERIMENTAL
Intervention: AGN 192024
Number of subjects: 25
Study: 10359882

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Methylprednisolone (40 mg/1.73 m2)
Number of subjects: 6
Study: 7662379

Group type: EXPERIMENTAL
Intervention: Bioflo valve
Number of subjects: 170

Group type: COMPARATOR
Intervention: Carpentier‐Edwards valve
Number of subjects: 170
Study: 2712403

Group type: EXPERIMENTAL
Intervention: 30 ml of 0.3 M sodium citrate solution orally 5 min before induction of anaesthesia (group C)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group without antacids (group T)
Number of subjects: 52
Study: 2560

Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg b.w.)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Bromazepam (0.1 mg/kg b.w.)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Insulin + Bromazepam
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline (2ml)
Number of subjects: 4
Study: 31630153

Group type: EXPERIMENTAL
Intervention: Cobitolimod
Number of subjects: 0
Study: 31180866

Group type: EXPERIMENTAL
Intervention: RSDE (Rama torsion angle and secondary structure feature‐guided differential evolution)
Number of subjects: 28
Study: 27533077

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy delivered via mail
Number of subjects: 1047
Study: 25779708

Group type: EXPERIMENTAL
Intervention: Morphine injection
Number of subjects: 72

Group type: COMPARATOR
Intervention: Morphine-midazolam solution
Number of subjects: 72